Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.35 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3936374 | 0.86 | HPGD (0.46) | NPC1RAB9AHPGDNPSR1GAA | |
| SCHEMBL3935331 | 0.84 | HTT (0.42) | RAB9AHPGDNPSR1SMN1; SMN2CYP3A4 | |
| SCHEMBL20847860 | 0.82 | HPGD (0.46) | NPC1RAB9AHPGDNPSR1SMN1; SMN2 | |
| SCHEMBL3927038 | 0.82 | HPGD (0.46) | NPC1RAB9AHPGDNPSR1GAA | |
| SCHEMBL849646 | 0.82 | HPGD (0.46) | NPC1RAB9AHPGDSMN1; SMN2CYP3A4 | |
| SCHEMBL18190692 | 0.81 | NPC1 (0.45) | NPC1RAB9AHPGDGAASMN1; SMN2 | |
| SCHEMBL1397668 | 0.81 | HPGD (0.41) | NPC1RAB9AHPGDNPSR1SMN1; SMN2 | |
| SCHEMBL879697 | 0.80 | NOTUM (0.46) | NPC1RAB9AHPGDNPSR1SMN1; SMN2 | |
| SCHEMBL25159676 | 0.79 | AAK1 (0.46) | NPC1RAB9ASMN1; SMN2AAK1HTT | |
| SCHEMBL29395253 | 0.79 | AAK1 (0.46) | NPC1RAB9ASMN1; SMN2AAK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107635970-B | Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3288936-B1 | BENZIMIDAZOLONE AND BENZOTHIAZOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| WO-2009007259-A1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007259-A1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-15 | — | — | WO | disclosed |
| US-20090012311-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012311-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| US-20090012311-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES | F. HOFFMAN-LA ROCHE AG (CH) | 2009-01-08 | — | — | US | disclosed |
| EP-2011783-A1 | Process for the preparation of an indole derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| EP-2011783-A1 | Process for the preparation of an indole derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| US-6503907-B2 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002051844-A1 | INDOLE DERIVATIVES AND THEIR USE AS 5-HT2B AND 5-HT2C RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-04 | — | — | WO | disclosed |
| WO-2002050041-A1 | DIHYDROINDOLE AND TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002044149-A1 | INDOLE AND DIHYDROINDOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-06 | — | — | WO | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
| WO-2002010169-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012311-A1 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES | IDO1, IDO2, TPH1 | NPC1 2444/4885RAB9A 1902/4885HPGD 158/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | NPC1 107/4885RAB9A 3381/4885HPGD 1383/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | NPC1 627/4885RAB9A 1839/4885HPGD 2929/4885 |
| US-20030004156-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | NPC1 171/4885RAB9A 1287/4885HPGD 63/4885 |
| US-20020103247-A1 | Indole derivatives or dihydroindole derivatives or salts are useful for the treatment of diseases associated with 2,3-oxidosqualene-lanosterol cyclase such as gallstone, tumorhypercholesterolemia, hyperlipemia, arterioscerosis etc. | LSS, CYP51A1, DHCR7 | NPC1 144/4885RAB9A 2320/4885HPGD 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.